NCT06052852 2025-11-17
Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies
Bolt Biotherapeutics, Inc.
Phase 1 Terminated
Bolt Biotherapeutics, Inc.
Omega Therapeutics
Huazhong University of Science and Technology
Medikine, Inc.